SQZB (SQZ Biotechnologies Co) 1-Year Sharpe Ratio: -0.95 (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SQZB SQZ Biotechnologies Co SQZB
12 GF Score
Price $0.02
View Full Analysis

What is SQZ Biotechnologies Co 1-Year Sharpe Ratio?

SQZ Biotechnologies Co SQZB 12 1-Year Sharpe Ratio is -0.95 as of Sep. 09, 2026. GuruFocus rates SQZB with a GF Score™ of 12/100.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-09-09), SQZ Biotechnologies Co's 1-Year Sharpe Ratio is -0.95.

SQZ Biotechnologies Co  (OTCPK:SQZB) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

SQZ Biotechnologies Co 1-Year Sharpe Ratio Related Terms

SQZB vs AGTX, ISCO, VYNT: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, SQZ Biotechnologies Co's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SQZ Biotechnologies Co 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SQZ Biotechnologies Co's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where SQZ Biotechnologies Co's 1-Year Sharpe Ratio falls into.


SQZB
12GF Score
SQZ Biotechnologies Co SQZB
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SQZ Biotechnologies Co 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.95 mean?
SQZ Biotechnologies Co (SQZB) has a 1-Year Sharpe Ratio of -0.95 as of Sep. 09, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for SQZ Biotechnologies Co and its competitors.
Is SQZ Biotechnologies Co's 1-Year Sharpe Ratio too high?
SQZ Biotechnologies Co's current 1-Year Sharpe Ratio is -0.95. Overall, SQZ Biotechnologies Co has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SQZ Biotechnologies Co's 1-Year Sharpe Ratio compare to AGTX and ISCO?
SQZ Biotechnologies Co's 1-Year Sharpe Ratio of -0.95 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Biotechnology company?
A good 1-Year Sharpe Ratio depends on the Biotechnology industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for SQZ Biotechnologies Co and its competitors. SQZ Biotechnologies Co's current 1-Year Sharpe Ratio is -0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SQZ Biotechnologies Co stock overvalued right now?
SQZ Biotechnologies Co (SQZB) has a current 1-Year Sharpe Ratio of -0.95. The current 1-Year Sharpe Ratio is -0.95. SQZ Biotechnologies Co's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For SQZ Biotechnologies Co (SQZB), the current 1-Year Sharpe Ratio is -0.95 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SQZ Biotechnologies Co Business Description

Address 200 Arsenal Yards Boulevard, Suite 210, Watertown, MA, USA, 02472
SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.
12GF Score

Get the complete analysis for SQZB

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price